Abstract 45P
Background
Despite the remarkable efficacy of immune checkpoint inhibitor(ICI)-based immunotherapy in various cancers, it still faces prominent issues such as a limited population benefiting from the treatment. Numerous studies have shown that the gut microbiome can participate in immune modulation. Therefore, utilizing the gut microbiome to accurately predict the effectiveness of immunotherapy, thereby achieving precision diagnosis and treatment, has become a research hotspot.
Methods
Metagenomic sequencing was conducted on stool samples from patients receiving ICIs across three centers. Machine learning techniques were employed for model development, while SHapley Additive explanations (SHAP) were utilized to interpret the models.
Results
Distinct characteristics were observed in the gut microbiome between patients with different responses to ICIs. The areas under the receiver operating characteristic curve (0.81 in the validation cohort) and the precision-recall curve (0.80 in the validation cohort) demonstrated that the gut microbiome signature (GMS) exhibited excellent predictive performance. SHAP analysis identified the top five taxa driving GMS predictions: Anaerobutyricum hallii, Bacteroides eggerthii, Faecalibaculum rodentium, Clostridiales bacterium, and Anaerostipes hadrus. Survival analysis indicated that GMS also has prognostic value, showing significant associations with overall survival (P value < 0.001 for both log-rank test and multivariate Cox analysis) and progression-free survival (P value < 0.001 for log-rank test and P value = 0.008 for multivariate Cox analysis). In the validation cohort, GMS outperformed traditional single gut microbiome biomarkers (P value > 0.05) in terms of predictive performance (P value < 0.05).
Conclusions
The GMS demonstrated excellent performance in predicting responses to ICIs and prognosis, positioning it as a promising new generation of non-invasive biomarkers for evaluating ICIs efficacy. The taxa identified through SHAP analysis may serve as potential targets for enhancing the effectiveness of ICIs.
Legal entity responsible for the study
D-X. Wang.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
185P - Characterizing the metabolic reprogramming of mutant ß-catenin in hepatocellular carcinoma
Presenter: Nathalie Wong
Session: Poster Display session
Resources:
Abstract
186P - Unveil and overcome PD(L)1 antibody resistance via functional genomics and clinical derived biopsies
Presenter: BIN XIE
Session: Poster Display session
Resources:
Abstract
187P - Single-cell RNA sequencing elucidates the role of intercommunication between epithelial cells, immune cells, and fibroblasts in high-grade serous ovarian cancer
Presenter: Xiaoting Zhao
Session: Poster Display session
Resources:
Abstract
188P - Single-cell and spatial transcriptomics delineate the microstructure and immune landscape of intrahepatic cholangiocarcinoma in the leading-edge area
Presenter: Zuyin li
Session: Poster Display session
Resources:
Abstract
189P - Image-guided labeling of live cells in tertiary lymphoid structures for single-cell transcriptomics
Presenter: Mengrui Cao
Session: Poster Display session
Resources:
Abstract
190P - Ex vivo modeling of precision immuno-oncology responses in lung cancer
Presenter: Bassel Alsaed
Session: Poster Display session
Resources:
Abstract
191P - Patient-derived 3D-bioprinted tumours as a relevant and innovative tool for immunotherapeutic testing.
Presenter: Kamila Pawlicka
Session: Poster Display session
Resources:
Abstract
192P - A new neuroendocrine model and in vitro effect of melatonin and serotonin on the PD-L1 ligand and its immunomodulatory action
Presenter: Dulce Caraveo Gutiérrez
Session: Poster Display session
Resources:
Abstract
193P - Humanized mice applying CD47; Prkcd; IL2rg triple KO mice exhibit enhanced human immune cell engraftment and reduced GvHD symptoms
Presenter: Seung-Ho Heo
Session: Poster Display session
Resources:
Abstract
194P - The impact of BTK inhibitors on ?d T cell fitness: Lesson for immunotherapy
Presenter: Adam Michalski
Session: Poster Display session
Resources:
Abstract